Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization.
Adherex Technologies Inc, under license from McGill University, is developing ADH-1, an intravenous N-cadherin antagonist that specifically disrupts the disorganized interactions between N-cadherin molecules in tumor blood vessels, as a potential anticancer compound. By May 2005, ADH-1 was in phase Ib/II clinical trials in Europe and the US, and phase II clinical trials in Canada.
Kelland
Lloyd
L
University College London, Cancer Research Technology Development Laboratories, Gower Street, WCV1E 6BT, London, UK. lkelland@cancertechnology.com
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D015820:Cadherins / Q000037:antagonists & inhibitors*; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D009842:Oligopeptides / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D010456:Peptides, Cyclic / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*
C518575:ADH-1 pepide; D020533:Angiogenesis Inhibitors; D015820:Cadherins; D009842:Oligopeptides; D010456:Peptides, Cyclic